selpercatinib和pralsetinib在RET融合阳性非小细胞肺癌中的匹配调整间接比较。

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-06-03 DOI:10.1080/14796694.2025.2508132

Maximilian Hochmair, Urpo Kiiskinen, Yulia D'yachkova, Tarun Puri, Xuwen Wang, Sorrel Wolowacz, Adrian Vickers, Ernest Nadal

{"title":"selpercatinib和pralsetinib在RET融合阳性非小细胞肺癌中的匹配调整间接比较。","authors":"Maximilian Hochmair, Urpo Kiiskinen, Yulia D'yachkova, Tarun Puri, Xuwen Wang, Sorrel Wolowacz, Adrian Vickers, Ernest Nadal","doi":"10.1080/14796694.2025.2508132","DOIUrl":null,"url":null,"abstract":"Aims: Selpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.Materials & methods: Efficacy and safety were compared using matching-adjusted indirect comparison.Results: Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.Conclusion: Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1867-1878"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150609/pdf/","citationCount":"0","resultStr":"{\"title\":\"Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.\",\"authors\":\"Maximilian Hochmair, Urpo Kiiskinen, Yulia D'yachkova, Tarun Puri, Xuwen Wang, Sorrel Wolowacz, Adrian Vickers, Ernest Nadal\",\"doi\":\"10.1080/14796694.2025.2508132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aims: Selpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.Materials & methods: Efficacy and safety were compared using matching-adjusted indirect comparison.Results: Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.Conclusion: Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1867-1878\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150609/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2508132\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2508132","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：Selpercatinib和pralsetinib被批准用于ret重排非小细胞肺癌。材料与方法：采用匹配调整间接比较法比较两种药物的疗效和安全性。结果：selpercatinib和pralsetinib的中位无进展生存期（PFS）分别为22.1和13.3个月(HR = 0.67；95% ci, 0.53-0.85)。客观有效率为64.5%、65.8%，疾病控制率为92.1%、90.4%。selpercatinib和pralsetinib的中位总生存期分别为43.9个月和43.9个月(HR = 0.81；95% ci, 0.60-1.09)。39.3%和62.6%的患者报告了≥3级治疗相关不良事件（TRAEs），分别有3.6%和10.0%的患者因TRAEs而停药。结论：结果相似；然而，selpercatinib显著延长了PFS，减少了≥3级trae。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.

Aims: Selpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.

Materials & methods: Efficacy and safety were compared using matching-adjusted indirect comparison.

Results: Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.

Conclusion: Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.